GEAP202416407A - Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors - Google Patents
Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitorsInfo
- Publication number
- GEAP202416407A GEAP202416407A GEAP202416407A GEAP2024016407A GEAP202416407A GE AP202416407 A GEAP202416407 A GE AP202416407A GE AP202416407 A GEAP202416407 A GE AP202416407A GE AP2024016407 A GEAP2024016407 A GE AP2024016407A GE AP202416407 A GEAP202416407 A GE AP202416407A
- Authority
- GE
- Georgia
- Prior art keywords
- oxopiperazine
- carboxamides
- cycloheteroalkyl
- cycloalkyl
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185637P | 2021-05-07 | 2021-05-07 | |
| US202163286691P | 2021-12-07 | 2021-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP202416407A true GEAP202416407A (en) | 2024-03-25 |
Family
ID=81927873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202416407A GEAP202416407A (en) | 2021-05-07 | 2022-05-05 | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| GEAP202216407A GEP20257795B (en) | 2021-05-07 | 2022-05-05 | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202216407A GEP20257795B (en) | 2021-05-07 | 2022-05-05 | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220380338A1 (https=) |
| EP (1) | EP4334293A1 (https=) |
| JP (3) | JP7522943B2 (https=) |
| KR (1) | KR20240005878A (https=) |
| CN (1) | CN117881664A (https=) |
| AR (1) | AR125786A1 (https=) |
| AU (1) | AU2022270115B2 (https=) |
| BR (1) | BR112023023239A2 (https=) |
| CA (1) | CA3217565A1 (https=) |
| CL (1) | CL2023003295A1 (https=) |
| CO (1) | CO2023015096A2 (https=) |
| CR (1) | CR20230519A (https=) |
| DO (1) | DOP2023000242A (https=) |
| EC (1) | ECSP23083881A (https=) |
| GE (2) | GEAP202416407A (https=) |
| IL (1) | IL308215A (https=) |
| JO (1) | JOP20230284A1 (https=) |
| MX (1) | MX2023013146A (https=) |
| PE (1) | PE20250021A1 (https=) |
| TW (1) | TWI827037B (https=) |
| WO (1) | WO2022235859A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013147A (es) * | 2021-05-07 | 2023-11-28 | Merck Sharp & Dohme Llc | Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8. |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| TW202523312A (zh) * | 2023-10-16 | 2025-06-16 | 美商克洛諾斯生技有限公司 | 離胺酸乙醯基轉移酶抑制劑 |
| CN117645533B (zh) * | 2023-10-20 | 2024-10-11 | 泰州精英化成医药科技有限公司 | 一种4-(三氟甲基)环己酮的合成方法 |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| CN117567323A (zh) * | 2023-10-30 | 2024-02-20 | 湖北泰盛化工有限公司 | 一种(s)-4-氯-2-((甲氧基羰基)氨基)丁酸乙酯的制备方法 |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52122392A (en) * | 1976-04-07 | 1977-10-14 | Sangyo Kagaku Kenkyu Kyokai | Novel antibacterials |
| EP1723129A1 (en) * | 2003-12-18 | 2006-11-22 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| CN101883760A (zh) | 2007-10-11 | 2010-11-10 | 沃泰克斯药物股份有限公司 | 用作电压-门控钠通道抑制剂的杂芳基酰胺类 |
| CA2702101A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| AU2008310661A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| WO2011026240A1 (en) * | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| US8889863B2 (en) * | 2010-07-16 | 2014-11-18 | Vanderbilt University | Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds |
| AU2014212431B2 (en) | 2013-01-31 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| KR102295748B1 (ko) | 2013-01-31 | 2021-09-01 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드 |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| ES2654393T3 (es) | 2013-07-19 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Sulfonamidas como moduladores de los canales de sodio |
| LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| JP2017114764A (ja) * | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
| WO2015184383A1 (en) * | 2014-05-29 | 2015-12-03 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles and methods of making and using same |
| KR101844984B1 (ko) | 2016-05-31 | 2018-04-03 | 한림대학교 산학협력단 | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| AU2018371216B2 (en) * | 2017-11-23 | 2024-09-19 | Oslo University Hospital Hf | Treatment of tachycardia |
| WO2019226931A1 (en) * | 2018-05-25 | 2019-11-28 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2020092187A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
| EP3873893A1 (en) * | 2018-11-02 | 2021-09-08 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| US20230114728A1 (en) * | 2019-11-26 | 2023-04-13 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| BR112022024476A2 (pt) * | 2020-06-17 | 2022-12-27 | Merck Sharp & Dohme Llc | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 |
| GEP20257750B (en) * | 2020-06-17 | 2025-03-25 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
-
2022
- 2022-05-05 EP EP22727539.3A patent/EP4334293A1/en active Pending
- 2022-05-05 TW TW111116959A patent/TWI827037B/zh active
- 2022-05-05 IL IL308215A patent/IL308215A/en unknown
- 2022-05-05 AR ARP220101186A patent/AR125786A1/es unknown
- 2022-05-05 PE PE2023003016A patent/PE20250021A1/es unknown
- 2022-05-05 GE GEAP202416407A patent/GEAP202416407A/en unknown
- 2022-05-05 JP JP2023567928A patent/JP7522943B2/ja active Active
- 2022-05-05 CA CA3217565A patent/CA3217565A1/en active Pending
- 2022-05-05 AU AU2022270115A patent/AU2022270115B2/en active Active
- 2022-05-05 BR BR112023023239A patent/BR112023023239A2/pt unknown
- 2022-05-05 GE GEAP202216407A patent/GEP20257795B/en unknown
- 2022-05-05 CR CR20230519A patent/CR20230519A/es unknown
- 2022-05-05 CN CN202280048071.1A patent/CN117881664A/zh active Pending
- 2022-05-05 US US17/737,070 patent/US20220380338A1/en active Pending
- 2022-05-05 WO PCT/US2022/027763 patent/WO2022235859A1/en not_active Ceased
- 2022-05-05 MX MX2023013146A patent/MX2023013146A/es unknown
- 2022-05-05 KR KR1020237042098A patent/KR20240005878A/ko active Pending
-
2023
- 2023-11-01 DO DO2023000242A patent/DOP2023000242A/es unknown
- 2023-11-06 EC ECSENADI202383881A patent/ECSP23083881A/es unknown
- 2023-11-06 CL CL2023003295A patent/CL2023003295A1/es unknown
- 2023-11-06 JO JOJO/P/2023/0284A patent/JOP20230284A1/ar unknown
- 2023-11-07 CO CONC2023/0015096A patent/CO2023015096A2/es unknown
-
2024
- 2024-01-05 JP JP2024000646A patent/JP2024038267A/ja active Pending
-
2025
- 2025-12-18 JP JP2025264265A patent/JP2026048891A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7522943B2 (ja) | 2024-07-25 |
| MX2023013146A (es) | 2023-11-28 |
| JP2026048891A (ja) | 2026-03-17 |
| JOP20230284A1 (ar) | 2023-11-06 |
| CL2023003295A1 (es) | 2024-07-12 |
| ECSP23083881A (es) | 2023-12-29 |
| EP4334293A1 (en) | 2024-03-13 |
| DOP2023000242A (es) | 2023-12-15 |
| CN117881664A (zh) | 2024-04-12 |
| TW202308999A (zh) | 2023-03-01 |
| TWI827037B (zh) | 2023-12-21 |
| CA3217565A1 (en) | 2022-11-10 |
| KR20240005878A (ko) | 2024-01-12 |
| GEP20257795B (en) | 2025-09-25 |
| CR20230519A (es) | 2024-01-19 |
| US20220380338A1 (en) | 2022-12-01 |
| AU2022270115B2 (en) | 2025-08-07 |
| IL308215A (en) | 2024-01-01 |
| WO2022235859A1 (en) | 2022-11-10 |
| PE20250021A1 (es) | 2025-01-07 |
| CO2023015096A2 (es) | 2023-11-20 |
| AR125786A1 (es) | 2023-08-16 |
| AU2022270115A1 (en) | 2023-11-16 |
| BR112023023239A2 (pt) | 2024-01-23 |
| JP2024515895A (ja) | 2024-04-10 |
| JP2024038267A (ja) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20257795B (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| JOP20220342A1 (ar) | مركبات 2-أوكسو إيميدازوليدين -4- كربوكساميد كمثبطات لـ nav1.8 | |
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| MY196455A (en) | Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| GEAP202315648A (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| MX2023000798A (es) | Peptidos funcionalizados como agentes antivirales. | |
| MX2023005983A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| MX2023005984A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| MX2023001756A (es) | Peptidos funcionalizados como agentes antivirales. | |
| ZA202204666B (en) | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors | |
| MX2023006063A (es) | Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central. | |
| MX2024003459A (es) | Metodos de tratamiento de trastornos metabolicos. | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| ATE254098T1 (de) | Verbindungen die die tryptase-activität hemmen | |
| WO2019139956A3 (en) | Prevention and treatment of organ fibrosis | |
| MY206479A (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| MX2023002422A (es) | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. | |
| MX2024014728A (es) | Inhibidor de arginasa y composicion farmaceutica que comprende el mismo | |
| MX2025008456A (es) | Nuevos compuestos heterociclicos | |
| TW202617147A (zh) | Ｋｉｆ１８ａ抑制劑治療非小細胞肺癌的用途 | |
| MX2024014166A (es) | Inhibidores de ripk1 y metodos de uso |